{
  "docId": "019de076-bddf-713d-b5c2-6a8995d43cc7",
  "docSlug": "296d0f6148994ebf1cf19bb1f2080f15",
  "documentTitle": "AbCellera | Investor Presentation Deck | 22 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 22,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "other",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a standard drug pipeline asset summary format.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-bddf-713d-b5c2-6a8995d43cc7/7",
  "deckHref": "/decks/019de076-bddf-713d-b5c2-6a8995d43cc7",
  "deckJsonHref": "/decks/019de076-bddf-713d-b5c2-6a8995d43cc7.json",
  "deckAnchorHref": "/decks/019de076-bddf-713d-b5c2-6a8995d43cc7#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.32,
        "x": 0.09,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "ABCL635 is the first AbCellera-led asset derived from our GPCR and ion channel platform.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da42fa8c-779a-4ad5-92e1-a23f120d0924",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.48,
        "x": 0.47,
        "y": 0.13
      },
      "kind": "table",
      "text": "Molecule: ABCL635; Status: IND-enabling studies; Target: Undisclosed; MOA: Antagonist; Indication: Undisclosed; Therapeutic Area: Metabolic & endocrine; Market Opportunity: >$2B; Differentiation: First-in-class",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebff9554-47fe-49ff-8a52-34c2a4137426",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.09,
        "y": 0.13
      },
      "kind": "title",
      "text": "A potential first-in-class antibody therapy for metabolic and endocrine conditions.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09bca760-77d5-4dbd-aa5a-4e115ab03999",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 7,
      "beatId": "10062467-5003-447c-9393-5657b41fddcd",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The company showcases its pipeline and financial performance.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "65507a74-1d1d-4c5e-b23b-54733838a17f",
      "evidence": "The company showcases its pipeline and potential.",
      "position": 1,
      "objective": "The cost of not investing in AbCellera's pipeline",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.5,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}